Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD276 inhibitors(CD276 antigen inhibitors), MUC1 inhibitors(Mucin-1 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Preclinical | United States | 20 Apr 2026 | |
| Breast Cancer | Preclinical | United States | 20 Apr 2026 | |
| Colorectal Cancer | Preclinical | United States | 20 Apr 2026 | |
| Colorectal Cancer | Preclinical | United States | 20 Apr 2026 | |
| Head and Neck Neoplasms | Preclinical | United States | 20 Apr 2026 | |
| Head and Neck Neoplasms | Preclinical | United States | 20 Apr 2026 | |
| Lung Cancer | Preclinical | United States | 20 Apr 2026 | |
| Lung Cancer | Preclinical | United States | 20 Apr 2026 | |
| Malignant neoplasm of gastro-oesophageal junction | Preclinical | United States | 20 Apr 2026 | |
| Malignant neoplasm of gastro-oesophageal junction | Preclinical | United States | 20 Apr 2026 |






